BIOMAT Database Logo BIOMAT Database Logo

Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. 1993

J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Department of Internal Medicine, Sapporo Hokuyu Hospital, Japan.

Cytokine gene expression in peripheral blood mononuclear cells during the development of graft-versus-host disease (GVHD) in patients who underwent allogeneic bone marrow transplantation (allo BMT) was analysed using a semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR). The expression of interleukin (IL)-1 beta, IL-6, and tumour necrosis factor (TNF)-alpha mRNA was increased during the development of GVHD and the degree of this increment depended on the severity of the disease. IL-2 expression was not detected at all and interferon-gamma expression was not much changed during GVHD. In patients with hepatic veno-occlusive disease (VOD), another transplantation-related complication, the expression of IL-1 beta and TNF-alpha mRNA was increased but IL-6 mRNA expression showed little increase. These findings suggest that IL-1 beta, IL-6 and TNF-alpha produced by peripheral blood mononuclear cells play an important role in the development of GVHD. Furthermore, liver dysfunction due to GVHD or VOD may be distinguishable by this type of cytokine analysis. Analysis of cytokine mRNA expression in peripheral blood mononuclear cells after allogeneic bone marrow transplantation may provide important information concerning the immune response and the cytokine network system in marrow transplant patients.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation.
December 1993, Bone marrow transplantation,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation.
June 2005, Bone marrow transplantation,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Cytochemical analysis of peripheral blood mononuclear cells following allogeneic bone marrow transplantation: correlation of hydrolase expression with graft-versus-host disease.
November 1985, Blood,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Cytokine serum levels and acute graft versus host disease after allogeneic bone marrow transplantation.
January 1992, Haematologica,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Acute graft-versus-host disease after allogeneic bone marrow transplantation.
November 1983, Canadian Medical Association journal,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Chronic graft versus host disease after allogeneic peripheral blood transplantation.
March 2003, Haematologica,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Graft versus host disease following allogeneic bone marrow transplantation.
October 1992, Current opinion in immunology,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Graft-versus-host disease following allogeneic bone marrow transplantation.
December 1984, Japanese journal of clinical oncology,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
Gene Expression in Human Acute Cutaneous and Hepatic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation.
January 2006, Cancer genomics & proteomics,
J Tanaka, and M Imamura, and M Kasai, and N Masauzi, and A Matsuura, and H Ohizumi, and K Morii, and Y Kiyama, and T Naohara, and M Saitho
miR-181a Expression in Donor T Cells Modulates Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation.
May 2016, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!